Additionally, MM-111, a bispecific antibody targeting both HER2 and HER3, has demonstrated its potential in HER2-positive breast cancer, especially in overcoming resistance mechanisms driven by HER3 activation (NCT01097460) [459]. This evidence concerns the gene ERBB3 and breast carcinoma.